Ocrelizumab initiation in patients with MS: A multicenter observational study

Area of Science:

• Neurology
• Immunology
• Clinical Trials

Background:

• Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• B cell-depleting therapies, such as ocrelizumab, have emerged as significant treatment options for MS.
• Real-world data on ocrelizumab's efficacy and safety in diverse MS populations are crucial.

Purpose of the Study:

• To evaluate the real-world effectiveness and safety of ocrelizumab in patients with multiple sclerosis.
• To assess ocrelizumab's impact on disease course in both treatment-naive and previously treated MS patients.
• To provide Class IV evidence for ocrelizumab as a therapeutic option in MS management.

Main Methods:

• Retrospective data collection from 210 patients with MS across three major neurology centers.
• Analysis of patient characteristics, including disease type, prior treatments, and ocrelizumab administration.
• Evaluation of clinical outcomes such as relapse rates, disability progression, and documented side effects.

Main Results:

• Ocrelizumab treatment stabilized disease in 13% of relapsing MS patients (annualized relapse rate 0.17) and 5% of all MS patients showed disability progression.
• Twenty-six percent of patients had primary progressive MS (PPMS), while 74% had relapsing-remitting (RRMS) or active secondary progressive MS (aSPMS).
• Treatment was generally well-tolerated, with short-term side effects including infusion reactions and mild infections.

Conclusions:

• Ocrelizumab demonstrates efficacy in stabilizing both treatment-naive and pretreated patients with MS.
• The findings support ocrelizumab as a valuable treatment option, potentially following therapies like natalizumab or fingolimod.
• Further long-term studies are necessary to fully ascertain the safety profile and confirm these real-world findings.